Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Patient Resources
COVID-19 Patient Resource Center
Clinical Trials
Search Clinical Trials
Patient Notification System
What is Clinical Research?
Volunteering for a Clinical Trial
Understanding Informed Consent
Useful Resources
FDA Approved Drugs
Professional Resources
Research Center Profiles
Clinical Trial Listings
Market Research
FDA Approved Drugs
Training Guides
Books
Events
Newsletters
JobWatch
White Papers
Patient Education
SOPs
eCFR and Guidances
White Papers
Trial Listings
Advertise
COVID-19
iConnect
Sign In
Create Account
Sign Out
My Account
Home
» Pipeline
Pipeline
January 29, 2018
Company
Drug/Device
Medical Condition
Status
Apexian Pharmaceuticals
APX3330
advanced solid tumors
Phase I trials initiated
Bavarian Nordic
BN-Brachyury
cancer metastasis
Phase I trials initiated enrolling 10 subjects
Protalex
PRTX-100 (PRTX-100-203 Study)
persistent/chronic Immune Thrombocytopenia
Phase Ib trials initiated enrolling 30 subjects in Europe
IntelGenx
Montelukast VersaFilm
Alzheimer’s disease
Phase IIa trials initiated
Biomarck Pharmaceutical
BIO-11006
non-small cell lung cancer
Phase II trials initiated in India
Melinta Therapeutics
radezolid
bacterial vaginosis
Phase II trials initiated
TrovaGene
PCM-075 + Zytiga
metastatic castration-resistant prostate cancer
Phase II trials initiated enrolling 25 subjects
Evofem Biosciences
Amphora
prevention of urogenital chlamydia and gonorrhea in women
Phase IIb/III trials initiated enrolling 850 subjects in the U.S.
GC Pharma
GC1102
hepatitis B virus infection following liver transplantation
Phase II/III trials planned
Swedish Orphan Biovitrum
SOBI003
mucopolysaccharidosis type IIIA
Fast Track designation granted by the FDA
Astellas Pharma
gilteritinib
acute myeloid leukemia
Orphan Drug designation granted by the EC
BERG
BPM31510
pancreatic cancer
Orphan Drug designation granted by the FDA
Enzychem Lifesciences
EC-18
acute radiation syndrome
Orphan Drug designation granted by the FDA
Nohla Therapeutics
NLA101
hematopoietic stem cell transplantation
Orphan Drug designation granted by the EC
Omeros
OMS721
primary Immunoglobulin A nephropathy
Orphan Drug designation granted by the EMA
Orphazyme
arimoclomol
Niemann-Pick disease Type C
Rare Pediatric Disease designation granted by the FDA
Genmab
daratumumab (Darzalex) + bortezomib, melphalan and prednisone
newly diagnosed multiple myeloma
Priority Review granted by the FDA
Baxter International
Bivalirudin
anticoagulant in patients undergoing percutaneous coronary intervention
FDA approved
Bristol-Myers Squibb
Yervoy (ipilimumab)
advanced (unresectable or metastatic) melanoma in pediatric patients 12 years of age and older
EC expanded indication approved
Takeda Pharmaceutical
Adcetris (brentuximab vedotin)
CD30-positive cutaneous T-cell lymphoma
EC extended current conditional marketing authorization
Upcoming Events
01
Dec
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
02
Dec
Clinical Trial Risk Management in the Post-COVID-19, All-Digital World: Predictive Transformation in Quality, Compliance and Risk Management
02
Dec
2020 in Review: Celebrating the Successes of the Clinical Research Community After A Difficult Year
10
Dec
Medical Device Clinical Trials in China: Latest Regulatory Developments
Featured Products
Regenerative Medicine: Steps to Accelerate Development
Clinical Trial Agreements: A Guide to Key Words and Phrases
Featured Stories
Simple Changes Can Make Trials More Patient Friendly
Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.
Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant
Ask the Experts: Trial Operations Adjustments in a Remote World
New!
2019 Site Survey Reports
Learn More Here
